Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • emc易倍官网入口Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • emc易倍官网入口Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • emc易倍官网入口Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • emc易倍官网入口Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • emc易倍官网入口 Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • emc易倍官网入口 Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • emc易倍官网入口Leadership
    • emc易倍官网入口History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • emc易倍官网入口Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • emc易倍官网入口Oncology
      • Rare Disease
      • Neuroscience
    • emc易倍官网入口Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • emc易倍官网入口Lay Summaries
      • emc易倍官网入口Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • emc易倍官网入口People
    • emc易倍官网入口Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€160.20

 €-0.40 (-0.25%)

  • emc易倍官网入口Media Resources
  • Annual Report
  • emc易倍官网入口 Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • emc易倍官网入口Terms and Conditions
  • emc易倍官网入口Cookie Policy
  • emc易倍官网入口Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?






2026-05-24 18:03:55